psoriasis

News

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

J&J's oral IL-23 drug backed for psoriasis in EU

J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Dr Jörn Drappa, Alumis' chief medical officer

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

J&J's oral IL-23 drug backed for psoriasis in EU

New biotech Avere plots listing via NextCure merger

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

J&J gets FDA okay for psoriasis drug icotrokinra

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

psoriasis

Editor's Picks